Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea

Clinical Infectious Diseases

Volumn 43, Issue 5, 2006, Pages 547-552

  Lagrotteria, Danny ^a   Holmes, Serena ^b   Smieja, Marek ^a,b   Smaill, Fiona ^a,b   Lee, Christine ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; RIFAMPICIN;

AGED; ANTIBACTERIAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; HOSPITAL PATIENT; HUMAN; KAPLAN MEIER METHOD; MALE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; SINGLE BLIND PROCEDURE; SYMPTOMATOLOGY; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; AGED; ANTI-BACTERIAL AGENTS; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; MALE; METRONIDAZOLE; RIFAMPIN;

EID: 33747603490     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/506354     Document Type: Article

References (16)

1. Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993; 17:109-13.
2. Sharma AK, Holder FE. Clostridium difficile diarrhea after use of tac-rolimus following renal transplantation. Clin Infect Dis 1998; 27:1540-1.
3. McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 1990; 162:678-84.
4. Barbut F, Petit JC. Epidemiology of Clostridium difficile-associated infections. Clin Microbiol Infect 2001; 7:405-10.
5. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004; 171:33-8.
6. Olson MM, Shanholtzer CJ, Lee JT Jr, Gerding DN. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol 1994; 15:371-81.
7. De Lalla F, Nicolin R, Rinaldi E, et al. Prospective study of oral tei-coplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 1992; 36:2192-6.
8. Teasley D, Gerding D, Olson M, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 1983; 2:1043-6.
9. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole and fusidic acid for the treatment of C. difficile-associated diarrhea. Clin Infect Dis 1996; 22:813-8.
10. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995; 44(RR-12):1-13.
11. Buggy BP, Fekety R, Silva J. Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol 1987; 9:155-9.
12. Barbut F, Decre D, Burghoffer B, et al. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother 1999; 43:2607-11.
13. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr. Society for Healthcare Epidemiology of America position paper on Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995; 16:459-77.
14. Bristol stool scale. Available at: http://en.wikipedia.org/wiki/Bris tol_Stool_Scale. Accessed 13 December 2005.
15. Wilcox M, Spencer R. Clostridium difficile infection: responses, relapses and reinfections. J Hosp Infect 1992; 22:85-92.
16. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27:1169-72.